The source of matrix-degrading enzymes in human cancer: Problems of research reproducibility and possible solutions

Daniel H. Madsen and Thomas H. Bugge

Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892

Matrix degradation is central to tumor pathogenesis. Enzymes that degrade extracellular matrix are abundant in tumors. But which out of the complex mixture of cells that form a tumor produces them? Surprisingly, several hundred studies devoted to this question have provided confusion rather than clarity. Our analysis of these studies identifies likely reasons as to why this may be the case, which has implications for the broader issue of research reproducibility.

Tumor invasion—that is, the infiltration, dissolution, and eventual substitution of normal tissues with tumor tissue—is a hallmark of human cancer and is key to the morbidity and mortality of the disease. The process involves the complete degradation of the preexisting extracellular matrix scaffolds of the invaded tissue concomitant with the formation of a new tumor-derived extracellular matrix that supports the continued expansion of the tumor mass (Jones and De Clerck, 1982; Liotta et al., 1983; Danø et al., 1985; Liotta, 1985; Tryggvason et al., 1987; Lu et al., 2012). Tumors consist of malignant cells and an assortment of nonmalignant cells, termed stromal cells (Fig. 1). The most abundant stromal cells are fibroblasts and macrophages, but other cell types, such as lymphocytes, neutrophils, mast cells, myoepithelial cells, endothelial cells, lymphendothelial cells, and platelets may also be present (Ehrlich, 1907; Borst, 1924; Engels et al., 2012; Gajewski et al., 2013; Galdiero et al., 2013; Ribatti, 2013; Noy and Pollard, 2014; Öhlund et al., 2014; Sharma et al., 2014). It is a widely held notion that matrix dissolution in human cancer is initiated by the release from the tumor of a limited number of hydrolytic enzymes that are unique in that they display potent enzymatic activity toward intact extracellular matrices (Liotta et al., 1982; Sloane and Honn, 1984; Danø et al., 1985). But which cells, among the diverse population of cell types that constitute a human tumor, produce these enzymes? Despite intense research, there is no clear answer to this question, which is not merely an academic one. Rather, it is central to being able to productively model human tumor invasion in animals and in cell-based ex vivo assays of extracellular matrix dissolution, which is key to the successful development of much-needed novel cancer therapeutics. Moreover, serious problems with reproducing preclinical cancer research have recently been uncovered (Prinz et al., 2011; Begley and Ellis, 2012). These problems are a major concern and may jeopardize both successful cancer therapy development and the integrity of the research field. Here, we set out to critically evaluate the published cancer research literature in order to identify the cellular sources of extracellular matrix-degrading enzymes in human cancer. In the process, we identified possible reasons for the lack of consensus in the field, which may be important to other fields as well and are relevant to the current dialogue on research reproducibility.

A widely discrepant literature

To obtain insights into the cellular sources of matrix-degrading enzymes in human cancer, we performed a literature analysis spanning the last two-and-a-half decades. Due to the vastness of the existing literature, which was evident from our preliminary search, we limited our analysis to the study of four human cancers—breast, colon, lung, and prostate—because they are estimated to account for about half of all newly reported cancer cases and cancer deaths in the United States in 2014 (American Cancer Society, 2014). We focused our analysis on proteases with the capacity to degrade nondenatured interstitial collagen and fibrin, which are the two principal cross-linked protein matrices that are encountered by the expanding tumor mass (Dvorak, 1986; Hirao et al., 1998; Hotary et al., 2003; Palumbo et al., 2003; Rowe and Weiss, 2009). These enzymes were matrix metalloproteinase (MMP)-1 (interstitial collagenase, collagenase-1), MMP-2 (gelatinase A, Mr 72,000 type IV collagenase), MMP-13 (collagenase-3), MMP-14 (membrane-type-1 MMP), and urokinase-type plasminogen activator (uPA), which activates the ubiquitous and abundant fibrinolytic protease zymogen, plasminogen (Danø et al., 1985; Aimes and Quigley, 1995; Gill and Parks, 2011). We excluded MMP-8 because of the very low number of studies addressing the expression of MMP-8 in cancer. We compiled 452 datasets from 248 published studies in which the cellular expression of either of these five proteolytic enzymes was analyzed in a manner that provided spatial resolution (immunohistochemistry [IHC] or immunofluorescence [IF]) for protein detection or in situ hybridization for detection of mRNA. We were unable to...
evaluate protease localization in 161 of these datasets (from 109 research papers), because the cellular localization was not described by the authors or because no figure example of the IHC, IF, or in situ hybridization was included. This left a total of 291 datasets, which included 105 studies of breast cancer, 100 studies of colon cancer, 52 studies of lung cancer, and 34 studies of prostate cancer, with 41 studies analyzing the location of MMP-1, 119 studies of MMP-2, 17 studies of MMP-13, 45 studies of MMP-14, and 69 studies of uPA. The complete list of studies can be found in the supplemental material.

To our surprise, no consensus emerged from these studies as to the cellular source of any of these five proteases in any of the four human tumors. Some studies reported expression of the proteases exclusively by cancer cells, whereas other studies found expression exclusively in nonmalignant stromal cells, and yet other studies found expression of these proteases in both cancer cells and stromal cells (Fig. 2). Furthermore, the reported frequency with which the expression of these proteases was found in individual human tumors, in studies where this was reported, varied from infrequently to ubiquitously. Likewise, the reported fraction of cells within each individual tumor that expressed a given protease varied from a small percentage to all cells within the tumor. Also, some studies found expression of matrix-degrading proteases to be restricted to tumor tissue, whereas other studies also found expression in corresponding normal tissues, again with widely varying cellular locations and frequencies. In studies that found protease expression in stromal cells, incongruity in the reported identity of the nonmalignant protease-expressing cells was frequent. These striking discrepancies could not easily be explained by sampling bias, as the average number of tumors analyzed in each individual study was 108 (with a range of 4–1,420). Furthermore, a comparison of studies of histologically stage-matched tumors, such as ductal breast carcinoma in situ, matched Gleason score for prostate cancer, or matched Dukes classification for colon cancer, did not reveal a consistent pattern in the reported localization of the five proteases.

The remarkable absence of an inter-study consensus as to matrix-degrading protease location in human breast, colon, lung, and prostate cancer led us to investigate whether the detection method affected the reported protease localization. Studies on breast and colon cancer constituted the majority (70%) of all the evaluated studies, and we therefore focused on these two types of cancer for this analysis. We first divided the studies into those using IHC or IF, and those using in situ hybridization as the method of protease detection. We found a striking difference in the expression pattern reported based on IHC or IF and the expression pattern reported based on in situ hybridization. The majority of the IHC- or IF-based studies found that both cancer and stromal cells expressed the proteases (61% in breast cancer and 73% in colon cancer), with the remaining 39% and 27% of studies finding expression exclusively in either cancer cells or in stromal cells (Fig. 3 A). Within the in situ hybridization studies, 72% and 70% of the breast cancer and colon cancer studies, respectively, identified stromal cells as the sole source of the five proteases (Fig. 3 A). The remaining studies reported the proteases to be expressed in both stromal and cancer cells or in the cancer cells only. We found no consistency in terms of which of the five proteases were observed in cancer cells, or in both stromal and cancer cells. If we focused entirely on the studies that used radiolabeled probes for in situ hybridization, which made up the majority of the studies, we saw an even stronger consensus, wherein 79% (26 out of 33 studies) and 100% (11 out of 11 studies) of the studies of breast cancer and colon cancer, respectively, found the matrix-degrading proteases to be expressed exclusively by stromal cells (Fig. 3 B). The majority (68%) of the relatively few in situ hybridization studies that used nonradioactive DNA or oligonucleotide probes,
however, found the proteases to be expressed in both cancer and stromal cells, frequently in 100% of the cells. This relatively high inter-study consensus suggests that tumor stromal cells, and not tumor cells per se, may be the primary source of matrix-degrading protease in human breast and colon carcinomas. This finding is at odds with the high-level expression of matrix-degrading enzymes found in many established human breast and colon cancer cell lines. However, the degree to which these tumor cell lines, often established multiple decades ago, are representative of the tumors from which they derive in terms of expression of matrix-degrading proteases, is unclear. These cell lines may derive from rare subpopulations of tumor cells endowed with the capacity to be propagated ex vivo. Furthermore, the continuous growth under 2D culture conditions may have led to a phenotypic drift.

Why such inconsistency?

In summary, a large body of work, spanning more than two decades, has failed to provide a consensus as to the cellular source of extracellular matrix–degrading enzymes in four of the most clinically important human cancers. Why do different researchers, to this extraordinary degree, get different answers when studying the same question? The reason for this will have to remain a matter of speculation. However, our in-depth analysis of the literature would suggest that some of the following issues alone or in combination have contributed to this:

- Inherently low expression levels of extracellular matrix–degrading enzymes, as compared with, for example, structural components of the tumor stroma, making their detection technically challenging, particularly by IHC of IF. This problem may not be restricted to protease detection, but may extend to the detection of other low-abundance secreted proteins in malignant as well as nonmalignant tissues.
- Inconsistent fixation conditions for excised human tumor tissues, resulting in variable epitope and mRNA preservation, and an associated inter-study variability.
- Extensive reliance on manufacturer specifications or the use of antibodies in prior publications as validation of antibody specificity. In this regard, significant problems with quality control of commercial antibodies recently were highlighted by Bradbury and Plückthun (2015).
- The use of excessively long in situ hybridization probes with a propensity for cross-hybridization or, conversely, very short in situ hybridization probes with insufficient ability to visualize nonabundant mRNAs.
- Lack of markers to positively identify antibody-stained or hybridization signal–positive cell populations. Only 10% of the studies analyzed here used cell type–specific markers to identify protease-expressing cell populations.
- The failure to use multiple complementary approaches to validate findings: 87% of the published studies relied on a single antibody or in situ probe to identify protease-expressing cell populations in the four human cancers.

It should be mentioned, however, that contradictory findings were reported even for studies that were seemingly well controlled. In a very thorough study of breast cancer by Nielsen et al. (2001), they used seven different uPA antibodies and an in situ probe, combined with markers for myofibroblasts and myoepithelial cells (α-smooth muscle actin), macrophages (CD68), and endothelial cells (CD31). This study led to the conclusion that uPA is found almost exclusively in stromal cells. In contrast, Carriero et al. (1994), using six different uPA antibodies, reported localization of the protease predominantly to breast cancer cells.

Concluding remarks and recommendations

Knowledge of the cellular sources of matrix-degrading protease production is much needed to assess the validity of current models of human cancer invasion, to generate new models that faithfully replicate human cancer invasion, and to provide a more solid basis for the development of new cancer therapeutics aimed at interfering with matrix degradation. As revealed in our analysis, the identification of the cellular source of matrix-degrading protease expression in human cancer clearly has proven problematic. Therefore, to resolve this issue, future studies would need to apply more highly quality-controlled IHC(IF) and in situ hybridization studies as well as complementary approaches to determine the localization of protease protein and mRNA. These may also be useful to other fields where similar controversies may exist.

These include:
- Routine application on serial sections of several extensively validated antibodies for IHC and IF studies and multiple nonoverlapping probes for in situ hybridization studies. In both cases, identical staining/hybridization patterns should be used as the principal evidence for signal specificity, rather than, respectively,
absence of staining after primary antibody omission or lack of a hybridization signal from complementary sense probes.

• Critical evaluation of whether the subcellular staining pattern corresponds to the expected localization of the protease.
• mRNA and protease expression profiling of rigorously quality-controlled laser capture microdissected tumor cell populations.
• mRNA and protease expression profiling of immunologically isolated cell populations from human tumor tissues.

Future studies should also integrate the recent revolutionary advances in molecular classification of human cancers to tease out distinct protease expression profiles (if any) linked to each molecular subclass of human cancer. Likewise, these studies should take into consideration the remarkable complexity of the cellular tumor stroma revealed by recent research (Gajewski et al., 2013; Galdiero et al., 2013; Ribatti, 2013; Noy and Pollard, 2014; Öhlund et al., 2014; Sharma et al., 2014).

Journal publication and funding agency policies historically have not stimulated the execution of such time-, labor-, and cost-consuming, yet critically important studies. Encouragingly, however, the heightened awareness of problems with reproducibility of preclinical cancer research (Prinz et al., 2011; Begley and Ellis, 2012; Bradley and Plückthun, 2015) has triggered new initiatives involving representatives from major funding agencies, academic researchers, reviewers, journal editors, the pharmaceutical industry, and patient advocacy groups to provide improved guidelines for the execution and reporting of science (Landis et al., 2012; Collins and Tabak, 2014).

Online supplemental material
A complete list of studies is available as supplemental text. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.201501034/DC1.

We thank Drs. Silvio Gukind, Alfredo Molinolo, Daniel Lawrence, Karin List, and Mary Jo Danton for critically reviewing this manuscript. This work was supported by the NIDCR Intramural Research Program. The authors declare no competing financial interests in relation to the work described.

Submitted: 8 January 2015  
Accepted: 20 March 2015

References


Begley, C.G., and L.M. Ellis. 2012. Drug development: Raise standards for the pharmaceutical industry, and patient advocacy groups to provide new initiatives involving representatives from major funding agencies, academic researchers, reviewers, journal editors, the pharmaceutical industry, and patient advocacy groups to provide improved guidelines for the execution and reporting of science. J. Biol. Chem. 287:636–649.


